Bextra Related Published Studies
Well-designed clinical trials related to Bextra (Valdecoxib)
Reduction in opioid-related adverse events and improvement in function with parecoxib followed by valdecoxib treatment after non-cardiac surgery: a randomized, double-blind, placebo-controlled, parallel-group trial. [2009]
Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. [2008.03]
Utility and sensitivity of the sore throat pain model: results of a randomized controlled trial on the COX-2 selective inhibitor valdecoxib. [2007.07]
Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study. [2007.06]
Utility and Sensitivity of the Sore Throat Pain Model: Results of a Randomized Controlled Trial on the COX-2 Selective Inhibitor Valdecoxib. [2007.05.24]
Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain. [2007.03]
Valdecoxib for postoperative pain management after cesarean delivery: a randomized, double-blind, placebo-controlled study. [2006.09]
Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies. [2006.07]
The COX-2 specific inhibitor Valdecoxib versus tramadol in acute ankle sprain: a multicenter randomized, controlled trial. [2006.06]
Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: a randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325]. [2006.03.10]
A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. [2006.03]
Evaluation of preemptive valdecoxib therapy on initial archwire placement discomfort in adults. [2006.03]
Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. [2006.03]
A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. [2006.02]
The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. [2005.06]
Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. [2005.05]
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. [2005.03.17]
Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department: a randomized controlled trial. [2004.12]
Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. [2004.10]
Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. [2004.08]
Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. [2004.06]
Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial. [2004.05]
Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. [2003.11]
Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. [2003.10]
A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. [2003.07.01]
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. [2003.06]
The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. [2003.05]
The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. [2003.02]
Evaluation of efficacy, safety and tolerability of valdecoxib in osteo-arthritis patients--an Indian study. [2002.11]
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. [2002.10]
A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. [2002.09]
Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. [2002.09]
Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. [2002.08]
Valdecoxib does not impair platelet function. [2002.07]
Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. [2002.06]
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. [2002.05]
Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. [2002.04]
Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. [2002.03]
Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. [2002.01]
Well-designed clinical trials possibly related to Bextra (Valdecoxib)
Effects of cyclooxygenase inhibition on anastomotic healing following large bowel resection in a rabbit model--a randomized, blinded, placebo-controlled trial. [2009.05]
Effects of cyclooxygenase inhibition on anastomotic healing following large bowel resection in a rabbit model-a randomized, blinded, placebo-controlled trial. [2009.01.29]
Multimodal analgesia without parenteral narcotics for total knee arthroplasty. [2008.06]
Prospective randomized, double-blind, placebo-controlled study of pre- and postoperative administration of a COX-2-specific inhibitor as opioid-sparing analgesia in major colorectal surgery. [2007.01]
[Analgesia in colon surgery : Can the use of NSAIDs reduce the opioid consumption following conventional and laparoscopic interventions?] [2006.10]
Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity. [2006.08]
Influence of culture site-specific MIC distributions on the pharmacokinetic and pharmacodynamic properties of piperacillin/tazobactam and piperacillin: a data analysis. [2006.07]
Efficacy of a selective COX-2 inhibitor for controlling irregular uterine bleeding in DMPA users. [2006.06]
Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1. [2006.05.01]
Relative thromboembolic risks associated with COX-2 inhibitors. [2005.07]
The meaning of pain relief in a clinical trial. [2005.06]
The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery. [2005.02]
The analgesic effects that underlie patient satisfaction with treatment. [2004.07]
Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters. [2004.05]
Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. [2004.02]
Single doses of parecoxib sodium intravenously are as effective as ketorolac in reducing pain after oral surgery. [2003.09]
Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. [2003.09]
Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. [2003.04]
The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. [2002.09]
Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. [2002.08]
Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. [2002.01]
A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. [2001.10]
Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. [2001.09]
Other research related to Bextra (Valdecoxib)
Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. [2009.01]
A RANDOMISED COMPARISON OF PARECOXIB/VALDECOXIB AND PLACEBO FOR THE PREVENTION OF CYSTOID MACULAR EDEMA AFTER SCLERAL BUCKLING SURGERY. [2008.12.11]
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. [2008.04]
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. [2008.01]
The selective and non-selective cyclooxygenase inhibitors valdecoxib and piroxicam induce the same postoperative analgesia and control of trismus and swelling after lower third molar removal. [2007.08]
Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. [2007.08]
An effective dose of valdecoxib in experimental mouse models of pain. [2007.07]
Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis. [2007.06]
Preparation and properties of valdecoxib-hydroxypropyl beta-cyclodextrin inclusion complex. [2007.05]
Successful treatment of cystoid macular edema with valdecoxib. [2007.04]
Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. [2006.09]
Analgesic efficacy of valdecoxib for acute postoperative pain after bunionectomy. [2006.09]
Valdecoxib provides effective pain relief following acute ankle sprain. [2006.09]
Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib. [2006.09]
Forced-degradation study of valdecoxib as bulk drug and in tablet formulation by HPTLC. [2006.07]
Valdecoxib exposures reported to Texas poison centers during 2002-2004. [2006.05]
Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. [2006.03]
Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. [2005.11.25]
Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. [2005.10]
How celecoxib could be safer, how valdecoxib might have been. [2005.09]
Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat. [2005.05]
Valdecoxib-associated acute generalized exanthematous pustulosis. [2005.05]
Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. [2005.03.01]
A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. [2005.03]
Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. [2005.01]
Valdecoxib for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen. [2005.01]
Valdecoxib for the management of chronic and acute pain. [2005.01]
[The specific cox-2 inhibitor valdecoxib provides effective analgesia after inguinal hernia surgery] [2004.12]
Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. [2004.10]
Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. [2004.09.01]
Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. [2004.07]
[Reactive hypoglycaemia, a mysterious, insidious but non dangerous critical phenomenon] [2004.04]
Daptomycin. [2004]
Evaluation of the efficacy, safety and tolerability of valdecoxib gel (1%) in adult patients with painful inflammatory joint disease. [2003.12]
Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarization. [2003.09]
Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. [2003.07.10]
Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. [2003.04]
Valdecoxib: a review. [2003.03]
Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. [2003.02.15]
|
